Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells.

Neurol Neuroimmunol Neuroinflamm · 2018 · PMC6192691 · PMID 30345334

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

15 We found an increase in IFNγ + B cells in 2nd-line patients, which could result from the lower baseline level of this cytokine than in 1st-line patients, who in contrast showed a trend reduction in this cytokine.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.